Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are studying Canadian cancer patients who have rare genetic changes in their tumors, such as alterations in genes like ALK, EGFR, ROS1, BRAF, and KRAS G12C. These rare molecular alterations can affect how the cancer responds to certain targeted drugs called tyrosine kinase inhibitors TKIs. The study aims to better understand the natural history of these cancers and compare treatment outcomes, including side effects and patient-reported experiences, across different therapies. The study observes cancer patients who have received or are currently receiving TKIs or other targeted therapies. It includes three groups living patients with confirmed rare molecular alterations, deceased patients with such alterations, and a comparator group of cancer patients without these rare changes. Patient-reported outcomes are collected through surveys at baseline and every three months, especially when treatments change. Participants provide molecular testing reports and complete quality of life questionnaires regularly for up to 10 years. Researchers track progression-free survival or overall survival, the development of brain metastases, and economic impacts related to treatment. The study collects data from medical records and patient surveys to understand treatment patterns, effectiveness, and quality of life in the real-world Canadian context.
Actively Recruiting
This research focuses on improving clinical trial enrollment for patients living with cancer in Canada. It evaluates the Clinical Trials Navigator CTN program, which was initially piloted in Windsor, Ontario, and aims to help patients, families, and healthcare providers find and enter meaningful clinical trials across Canada. The study addresses the common barrier of limited trial availability at patients local cancer centers, especially in rural and smaller community hospitals where enrollment rates are lowest. The study uses a stepped wedge, cluster randomized controlled trial design to roll out the CTN program sequentially to twenty cancer centers over 12 months. The CTN program includes expert navigators who perform thorough searches for available trials, a publicly accessible referral process, continuous quality improvement, and knowledge sharing. Two groups are compared standard care processes for trial enrollment and the CTN program-assisted enrollment process. Participants include patients receiving treatment for breast cancer and healthcare professionals at participating centers. Data collection involves monthly physician surveys to track patient referrals and enrollments in trials outside their home centers, as well as structured interviews with stakeholders before and after CTN program implementation. The study measures referral rates to clinical trials, enrollment rates, stakeholder attitudes, barriers to referral and enrollment, and the CTN programs scalability. The entire study lasts 12 months with no follow-up beyond this period.
Actively Recruiting
Researchers are comparing two dosing strategies of epinephrine to improve survival among adults who experience out-of-hospital cardiac arrest OHCA caused by ventricular fibrillation VF or pulseless ventricular tachycardia pVT. This randomized controlled trial aims to determine if a lower total dose of epinephrine is not worse than the standard higher dose in helping patients survive until hospital discharge. The study is conducted across multiple centers and involves adults treated by paramedics during emergency resuscitation. Participants are randomly assigned to receive either a low cumulative dose of epinephrine up to 2mg total or the standard cumulative dose up to 6mg total. Paramedics start cardiopulmonary resuscitation CPR and deliver defibrillation shocks per their protocols. After initial defibrillation, intravenous access is established, and epinephrine doses are given every 3 to 5 minutes until the patient regains circulation or resuscitation ends. Additional medications and procedures like intubation may be used as needed. Patient follow-up is done using healthcare databases and phone interviews. During the study, researchers will collect information on survival to hospital discharge, return of spontaneous circulation, length of hospital and critical care stays, and other health outcomes up to five years after the cardiac arrest. They will also assess patients functional status, quality of life, anxiety, and depression at about one year. Safety and long-term health events such as re-hospitalizations and repeat cardiac arrests will be monitored, providing a thorough understanding of the effects of different epinephrine dosing strategies over time.
Actively Recruiting
This research aims to evaluate the harms and benefits of endocrine therapy in patients aged 70 years or older with lower-risk stage 1 hormone receptor-positive HR breast cancer. The current standard care includes breast-conserving surgery followed by radiotherapy and at least 5 years of endocrine therapy. However, in older patients, the benefit of endocrine therapy may be reduced due to higher risks of death from other causes and the presence of other health conditions that could affect quality of life and functional status. Participants will be randomly assigned to one of two groups either omission of endocrine therapy or administration of endocrine therapy for at least 5 years. Prior to this, they must have received standard local treatment, including breast-conserving surgery followed by radiotherapy or total mastectomy. The study is multicenter and randomized to assess the balance of benefits and harms associated with endocrine therapy in this older population. Throughout the study, participants will be followed for up to 5 years. Researchers will assess a hierarchical composite endpoint including overall survival, invasive disease-free survival, metastatic disease-free survival, and quality of life. Additional evaluations will include breast cancer-specific survival, treatment side effects, changes in geriatric health domains, adherence to endocrine therapy, and patient-reported symptoms such as hot flashes and joint pain. Quality of life questionnaires and belief assessments about therapy will be collected at multiple time points to monitor impact and treatment experiences.
Actively Recruiting
Researchers are investigating maridebart cafraglutide for people with obesity or overweight to evaluate its long-term effects on weight management, safety, and tolerability. This trial is an extension of a previous study trial 20210181 and aims to provide more information about how the drug works over an extended period. It is a phase 3, randomized, double-blind study sponsored by Amgen. Participants will receive different doses of maridebart cafraglutide or placebo depending on their treatment in the previous trial. Some will continue with low dose every 4 weeks, others will be re-randomized to receive medium or high doses on schedules of every 4, 8, or 12 weeks, or placebo injections every 4 weeks. Participants who had placebo before will undergo a dose-escalation phase before starting the high dose treatment. During the study, participants will be monitored for changes in body weight, waist circumference, quality of life, and any side effects or adverse events over about 48 weeks of treatment. The trial will assess how well weight loss is maintained and record any treatment-emergent adverse events up to 60 weeks. Participants will have regular visits for injections and safety assessments throughout the study period.
Actively Recruiting
Researchers are evaluating treatment strategies for transplant-ineligible older adults with newly diagnosed multiple myeloma. The study compares continuous use of anti-CD38 antibodies daratumumab or isatuximab alongside lenalidomide and dexamethasone against a fixed duration approach where these antibodies are stopped after about a year and a half. The goal is to determine if a shorter antibody treatment works as well as continuous therapy. Participants will be randomly assigned to one of two groups. One group will continue standard care with ongoing daratumumab or isatuximab combined with lenalidomide and dexamethasone. The other group will stop the antibody injections after completing 18-20 cycles but continue the other medications indefinitely as long as they benefit. The study includes two treatment arms one with lenalidomide and dexamethasone alone, and the other with those drugs plus daratumumab or isatuximab. During the trial, participants will undergo regular assessments including measurements of disease progression, survival, response rates, side effects, quality of life, and economic factors over a period of approximately 9 years. Researchers will monitor the safety and effectiveness of the treatments and gather data through questionnaires and clinical evaluations. Participants will remain on treatment as long as they continue to benefit and will be followed closely throughout the study duration.
1-10 of 25
1